Tromsø, Norway, 14. December 2020. ArcticZymes Technologies ASA (AZT) invites
shareholders to a virtual Q&A session regarding the Biotec BetaGlucans
divestment on Tuesday 15 December at 0830 CET.
CEO Jethro Holter will have a short introduction regarding the press release on
divestment of Biotec Betaglucans AS before opening for questions.
Participants who want to participate in the virtual meeting which will done over
"Teams" are asked to send an email to ir@arcticzymes.com for a separate
invitation.
Participants who want to participate by telephone should dial in on +47 21 40 24
87 97 with conference id: 752199536# It will be possible to ask questions
through "Teams" and over the phone after the introduction is completed.
-ENDS-
For more information, please contact:
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoll@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.
ArcticZymes Technologies' unique IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com